Alfuzosin for benign prostatic hypertrophyJARDIN, A; BENSADOUN, H; DELAUCHE-CAVALLIER, M. C et al.Lancet (British edition). 1991, Vol 338, Num 8772, issn 0140-6736, p. 947Article

Alfuzosin once daily facilitates return to voiding in patients in acute urinary retentionMCNEILL, S. A; HARGREAVE, T. B.The Journal of urology. 2004, Vol 171, Num 6, pp 2316-2320, issn 0022-5347, 5 p., 1Article

Alfuzosin for benign prostatic hypertrophyCHAPPLE, C. R.Lancet (British edition). 1991, Vol 338, Num 8760, issn 0140-6736, p. 182Article

Alfuzosin to Relieve Ureteral Stent Discomfort : A Prospective, Randomized, Placebo Controlled StudyBEDDINGFIELD, Richard; PEDRO, Renato N; HINCK, Bryan et al.The Journal of urology. 2009, Vol 181, Num 1, pp 170-176, issn 0022-5347, 7 p.Article

In Vitro Controlled Release of Alfuzosin Hydrochloride Using HPMC-Based Matrix Tablets and Its Comparison with Marketed ProductNAIR, Anroop; GUPTA, Rachna; VASANTI, Sutrave et al.Pharmaceutical development and technology. 2007, Vol 12, Num 6, pp 621-625, issn 1083-7450, 5 p.Article

Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 Mg alfuzosin once daily. CommentaryHARTUNG, R; MATZKIN, H; ALCARAZ, A et al.The Journal of urology. 2006, Vol 175, Num 2, pp 624-628, issn 0022-5347, 5 p.Article

Alfuzosin Stone Expulsion Therapy for Distal Ureteral Calculi : A Double-Blind, Placebo Controlled Study. CommentaryNARDI PEDRO, Renato; HINCK, Bryan; HENDLIN, Kari et al.The Journal of urology. 2008, Vol 179, Num 6, pp 2244-2247, issn 0022-5347, 4 p.Article

Gériatrie : Gare aux effets indésirables = Geriatrics: take care with side effectsLa Revue Prescrire. 2005, Vol 25, Num 257, issn 0247-7750, p. 39Article

Toxic epidermal necrolysis caused by alfuzosin, an α₁-adrenoceptor antagonist. CommentaryWANG, Yi-Shi; TAY, Yong-Kwang; KWOK, Colin et al.Archives of dermatology (1960). 2006, Vol 142, Num 7, pp 938-938, issn 0003-987X, 1 p.Article

Clinical and pressure-flow changes after long-term treatment with alfuzosin SRDE NUNZIO, C; FRANCO, G; LORI, F et al.Urologia Internationalis. 2003, Vol 71, Num 1, pp 31-36, issn 0042-1138, 6 p.Article

Alfuzosin improves penile erection triggered by apomorphine in spontaneous hypertensive ratsMAYOUX, Eric; RAMIREZ, Juan Fernando; POUYET, Thierry et al.European urology. 2004, Vol 45, Num 1, pp 110-116, issn 0302-2838, 7 p.Article

Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated Oral administrationMOTTET, Nicolas; BRESSOLLE, Francoise; DELMAS, Vincent et al.European urology. 2003, Vol 44, Num 1, pp 101-105, issn 0302-2838, 5 p.Article

Tratamiento farmacológico de la hiperplasia benigna de prótata = Medical treatment of benign prostatic hyperplasiaSANCHEZ DE MEDINA, F.Ars Pharmaceutica. 1995, Vol 36, Num 2, pp 281-283, issn 0004-2927Article

Chronic Pelvic Pain Syndrome and Semen Quality of Korean Men in Their Fourth DecadeJAE SANG BYUN; TAE KI YOON; HONG WOO RHEE et al.Journal of andrology. 2012, Vol 33, Num 5, pp 876-885, issn 0196-3635, 10 p.Article

Intraoperative Floppy Iris Syndrome Associated with α_I-Adrenergic Receptor AntagonistsCANTRELL, Matthew A; BREAM-ROUWENHORST, Heather R; STEFFENSMEIER, Andrew et al.The Annals of pharmacotherapy. 2008, Vol 42, Num 4, pp 558-563, issn 1060-0280, 6 p.Article

The influence of alpha₁ -adrenoreceptors on neuropeptide release from primary sensory neurons of the lower urinary tractTREUISANI, Marcello; CAMPI, Barbara; GATTI, Raffaele et al.European urology. 2007, Vol 52, Num 3, pp 901-908, issn 0302-2838, 8 p.Article

The Effects of Tolterodine Extended Release and Alfuzosin for the Treatment of Double-J Stent―Related SymptomsSEUNG CHOL PARK; SUNG WON JUNG; JEA WHAN LEE et al.Journal of endourology. 2009, Vol 23, Num 11, pp 1913-1917, issn 0892-7790, 5 p.Article

Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia : a 3-year experience in real-life practiceVALLANCIEN, Guy; EMBERTON, Mark; ALCARAZ, Antonio et al.BJU international (Papier). 2008, Vol 101, Num 7, pp 847-852, issn 1464-4096, 6 p.Article

Combination of phosphodiesterase-5 inhibitors and α-blockers in patients with benign prostatic hyperplasia : treatments of lower urinary tract symptoms, erectile dysfunction, or both?CARSON, Culley C.BJU international (Papier). 2006, Vol 97, pp 39-43, issn 1464-4096, 5 p., SUP2Article

Alfuzosin 10 mg once daily in the management of acute urinary retention: Results of a double-blind placebo-controlled study. Author's replyMCNEILL, S. A; HARGREAVE, T. B; ROEHRBORN, Claus G et al.Urology (Ridgewood, NJ). 2005, Vol 65, Num 1, pp 83-90, issn 0090-4295, 8 p.Article

Alfuzosin and Symptoms of Chronic Prostatitis-Chronic Pelvic Pain SyndromeNICKEL, J. Curtis; KRIEGER, John N; NADLER, Robert et al.The New England journal of medicine. 2008, Vol 359, Num 25, pp 2663-2673, issn 0028-4793, 11 p.Article

One-pot biocatalyzed preparation of substituted amides as intermediates of pharmaceuticalsBALDESSARI, Alicia; MANGONE, Constanza P.Journal of molecular catalysis. B, Enzymatic. 2001, Vol 11, Num 4-6, pp 335-341, issn 1381-1177Conference Paper

History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 yearsLUKACS, B; GRANGE, J. C; COMET, D et al.European urology. 2000, Vol 37, Num 2, pp 183-190, issn 0302-2838Article

One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaireLUKACS, B; GRANGE, J. C; COMET, D et al.Urology (Ridgewood, NJ). 2000, Vol 55, Num 4, pp 540-546, issn 0090-4295Article

Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studiesROEHRBORN, C. G; VAN KERREBROECK, P; NORDLING, J et al.BJU international (Papier). 2003, Vol 92, Num 3, pp 257-261, issn 1464-4096, 5 p.Article